Floatz logo

Zofran

Extra-Pulmonary Small Cell Carcinomas

National Cancer Institute (NCI)Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Extra-Pulmonary Small Cell Carcinomas cohort.

Asset / SponsorPhaseRating
Hycamtin
National Cancer Institute (NCI)
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
EpicentRx, Inc.
Phase 2BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Vinorelbine
EpicentRx, Inc.
Phase 2BB
Lurbinectedin
SystImmune Inc.
Phase 3BB

View all 31 →

Same molecule, other indications

Zofran is also rated in:

NauseaDormant
BBB
Indicative ·
73 / 100
View asset →
VomitingDormant
BBB
Indicative ·
73 / 100
View asset →
Non-Hodgkin's LymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →